Cetuximab is an intravenously administered epidermal growth factor receptor (EGFR) inhibitor used to treat advanced colorectal cancer, head and neck squamous cell carcinoma, pancreatic cancer, and less frequently, non-small cell lung cancer. This evidence concerns the gene EGFR and pancreatic neoplasm.